The Phase 1b lead-in trial, , which is enrolling up to 18 patients, is intended to identify the optimal dosage of HER-Vaxx for the study’s Phase 2, and to confirm the drug’s safety and immunogenecity. Phase 2 will involve approximately 68 patients and will be an open label study,randomised into two groups: HER-Vaxx plus standard-of-care(chemotherapy) and standard-of-care alone. The endpoints of Phase 2 will be safety, immune response, progression-free survival and overall survival.
all sounds good for moving forward
- Forums
- ASX - By Stock
- IMU
- November News Letter
November News Letter, page-2
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
|
|||||
Last
5.2¢ |
Change
-0.002(3.70%) |
Mkt cap ! $382.1M |
Open | High | Low | Value | Volume |
5.4¢ | 5.4¢ | 5.2¢ | $148.9K | 2.828M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
31 | 2436853 | 5.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.3¢ | 392814 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
31 | 2436853 | 0.052 |
43 | 4493294 | 0.051 |
58 | 4676760 | 0.050 |
19 | 2213068 | 0.049 |
20 | 815580 | 0.048 |
Price($) | Vol. | No. |
---|---|---|
0.053 | 392814 | 5 |
0.054 | 3612717 | 13 |
0.055 | 870851 | 7 |
0.056 | 2745820 | 14 |
0.057 | 859484 | 10 |
Last trade - 16.10pm 22/08/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |
The Watchlist
SS1
SUN SILVER LIMITED
Gerard O'Donovan, Executive Director
Gerard O'Donovan
Executive Director
SPONSORED BY The Market Online